Erlotinib and Cetuximab in Treating Lung Cancer Patients

Chase Cancer researchers reported at the annual session of the International Association for the Study of lung cancer, which has recently been discovered, breaking news. Non-small lung cancer patients, progress on a cetuximab-tion system can be erlotinib (Tarceva). Erlotinib (Tarceva) and cetuximab (Erbitux) plays the role of stopping the growth of cancer cells to block in some of the enzymes for cell growth. Although inhibition of epidermal growth receptor (EGFR), as well. Scientists estimate that, if a patient an inhibitor of EGFR progression to another inhibitor of EGFR "Just because a patient has made progress and an inhibitor of EGFR, does not necessarily mean that you come from a clinical benefit," said Hossein Borghaei Thursday, the doctors Onkologin Fox Chase. "And for patients who do not have a lot of options treatment, we believe that it is a good thing. It gives them another drug to try if the disease progresses. " Scientists have discovered that patients whose illness may no longer be treated with cetuximab efficiently on erlotinib. Borghaei and his team, a search for treatment and the results of the selection of patients, a Fox Chase clinical trials, a mixture of medicine cetuximab, carboplatin and paclitax, 53 patients who participated, and 15 patients with erlotinib and 3 patients remain on erlotinib. The 12 patients who are not in erlotinib erlotinib median duration of therapy was 63 days with a range of 36 to 222 days. The three other patients in treatment have been informed of the status of the drug for 41, 238 and 459 days. The median progression-free survival of 2.5 months for erlotinib was all 15 patients. After Borghaei, a subset of data, and analysis of a hypothesis. Frank C. Victor received cetuximab, 14 of 17 patients were a pustular erythematous, papular, follicular, and houses that have not complied with the cyst. Most areas of interest in a seborrhoeic facial distribution (for example, in the face, nose, nasolabial folds, cheeks, chin, and suburban). Based on the author. The erlotinib is used to treat lung cancer and non small cetuximab is like a drug in order. Characteristics of the tumor to predict the clinical benefit of erlotinib in progress on a scheme of cetuximab-tion has not yet been clarified. Dr. Borghaei, wants a search in future studies.